Aminopeptidase N and TNF receptors

The query 'Aminopeptidase N and TNF receptors' is scientifically inaccurate as it combines two distinct molecular entities: Aminopeptidase N (APN) and the Tumor Necrosis Factor Receptors (TNFRs), primarily TNFR1 and TNFR2. These are separate, independently druggable targets with different gene loci, structures, and mechanisms. Aminopeptidase N is a membrane-bound zinc-dependent metalloprotease involved in peptide metabolism, tumor angiogenesis, cell motility, cell adhesion, and serves as a receptor for certain coronaviruses. Overexpression is observed in multiple tumor types and the tumor vasculature, making it a validated target for anti-cancer and anti-angiogenic therapies. TNF receptors are cell-surface proteins that bind tumor necrosis factor (TNF) and mediate a wide range of biological effects including inflammation, cell survival, and apoptosis. Therapeutic targeting of these receptors (directly or via TNF ligand) has had major clinical impact in autoimmune and inflammatory diseases, and new approaches seek greater selectivity between TNFR1 and TNFR2 to minimize adverse effects. While some limited evidence suggests potential interactions between certain aminopeptidases and TNFR2, this does not constitute a single canonical or universally recognized therapeutic target. Therefore, this entry is marked as 'incorrect' due to its conflation of two fundamentally separate biological systems.

Other names

CD13membrane aminopeptidase Nalanyl aminopeptidaseTNFRSF1ATNFRSF1BCD120aCD120bp55 receptorp75 receptor

Competitive enzyme inhibition; ligand-directed peptide-drug conjugates targeting tumor vasculature (for APN). Antagonism (neutralizing TNF ligand, blocking receptor-ligand binding); Agonism (selective receptor activation/clustering); Decoy receptor action (for TNF receptors).